AEZS - Aeterna Zentaris, Inc.
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
Recently reported position changes by institutional investors
Recent trades by U.S. Senators
No data for this ticker
Recent trades by U.S. Representatives
| Date |
Rep. |
Type |
| 7/20/2017 |
Roger W. Marshall |
Sale |
| 7/19/2017 |
Roger W. Marshall |
Purchase |
Quarterly net insider trading by a company's directors and management
No data for this ticker
Flights by private jets registered to AEZS
No data for this ticker
Federal grants, loans, and purchases. Click on a date for more info.
No data for this ticker
